RELMADA THERAPEUTICS, INC.
For the period ended May 27, 2026. Filed Apr 17, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
May 27, 2026 · Filed Apr 17, 2026
Use the contents to explore the available documents and sections.
Contents
Pay versus Performance Information
The following table sets forth information concerning the compensation of our principal executive officer, or “PEO,” and, on an average basis, the compensation of our other named executive officers, or “NEOs,” for each of the fiscal years ending December 31, 2025, 2024, and 2023 as such compensation relates to our financial performance for each such fiscal year.
| Year · Summary Compensation Table Total for PEO(1) · Compensation Actually Paid to PEO(1)(2)(3) · Average Summary Compensation Table Total for Non-PEO NEO’s(1) · Average Compensation Actually Paid to Non-PEO NEO’s(1)(2)(4) · Value of Initial Fixed $100 Investment(5) Based on: · Net Income · Company- Selected Measure | ||||||||
|---|---|---|---|---|---|---|---|---|
| Total Shareholder Return · Peer Group Total Shareholder Return | ||||||||
| 2025 | $8,892,633 | $19,464,894 | $5,625,859 | $12,036,755 | $15.06 | * | $0 | * |
| 2024 | $1,800,723 | $(699,229) | $988,395 | $(19,975) | $1.62 | * | $0 | * |
| 2023 | $2,071,096 | $174,347 | $1,176,567 | $191,662 | $12.91 | * | $0 | * |
- Not required for smaller reporting companies
(1) For each of 2025, 2024 and 2023, the PEO is Sergio Traversa, Chief Executive Officer, and the non-PEO NEOs are Maged Shenouda, Chief Financial Officer, and Charles Ence, Chief Accounting and Compliance Officer. Paul Kelly, Chief Operating Officer is included in the 2025 row as a NEO.
(2) We do not have pensions; therefore, an adjustment to the Summary Compensation Table (SCT) totals related to pension value for any of the years in this table is not needed.
(3) To calculate Compensation Actually Paid (CAP) for the PEO, adjustments were made to SCT total compensation, calculated in accordance with the SEC methodology for determining CAP for each year. Adjustments to CAP of $10,577,552, $(2,499,952) and $(1,896,749) for the years 2025, 2024 and 2023, respectively, consisted solely of the change in value of prior years’ award unvested at the respective year end.
(4) To calculate Compensation Actually Paid (CAP) for the non-PEO NEO’s, adjustments were made to SCT total compensation, calculated in accordance with the SEC methodology for determining CAP for each year. Adjustments to CAP of $6,414,552, $(1,008,370) and $(954,905) for the years 2025, 2024 and 2023, respectively, consisted solely of the change in value of prior years’ award unvested at the respective year end.
(5) Total Shareholder Return assumes $100 was invested on December 31, 2020.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.